logo
Plus   Neg
Share
Email

Merck Announces Label Expansion For KEYTRUDA In Canada - Quick Facts

Merck (MRK) announced that Health Canada has expanded the label for KEYTRUDA (pembrolizumab), the company's anti-PD-1 therapy, to include approval for the treatment of metastatic non-squamous non-small cell lung cancer or NSCLC, in combination with pemetrexed and platinum chemotherapy, in adults with no EGFR or ALK genomic tumour aberrations, and no prior systemic chemotherapy treatment for metastatic NSCLC.

KEYTRUDA was first approved in Canada in 2015 and currently has eight indications in a number of disease areas, including non-small cell lung cancer, classical Hodgkin lymphoma, melanoma and bladder cancer.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Alibaba is upgrading its intellectual property system using blockchain technology, according to local news outlet Sohu. Alibaba Platform Management expects this to benefit mainly small and medium-sized enterprises, brands and entrepreneurs. The technology will be fully implemented in September, and thereafter, the company intends to expand it to the field of digital copyright protection. Electronics retailer Best Buy Co., Inc. (BBY) reported Thursday a 27 percent increase in profit for the first quarter from last year, which was impacted by restructuring charges, and higher revenues. Both adjusted earnings per share and revenues for the quarter topped analysts' estimates. The company also provides guidance for the second quarter and reiterated its outlook for the full-year 2020. While reporting financial results for the second quarter on Thursday, Hormel Foods Corp. (HRL) lowered its earnings and net sales guidance for the full-year 2019. For fiscal 2019, the company now projects earnings in a range of $1.71 to $1.85 per share, and net sales between $9.70 billion and $10.20...
Follow RTT